|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FUS1 is a tumor suppressor gene that has been found to be frequently lost in a variety of solid tumors.
|
29393096 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TUSC2 combined with anti-PD-1 induced tumor infiltrating more than NK and CD8<sup>+</sup> T cells and fewer MDSCs and Tregs than each agent alone, both in subcutaneous tumor and in lung metastases.
|
29339375 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Detection of high-grade neoplasia in air-dried cervical PAP smears by a microRNA-based classifier.
|
29328473 |
2018 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of the role of TUSC2 in regulating immune cells, we assessed TUSC2 efficacy on antitumor immune responses alone and in combination with anti-PD-1 in two <i>Kras</i>-mutant syngeneic mouse lung cancer models.
|
29339375 |
2018 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of the role of TUSC2 in regulating immune cells, we assessed TUSC2 efficacy on antitumor immune responses alone and in combination with anti-PD-1 in two <i>Kras</i>-mutant syngeneic mouse lung cancer models.
|
29339375 |
2018 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of the role of TUSC2 in regulating immune cells, we assessed TUSC2 efficacy on antitumor immune responses alone and in combination with anti-PD-1 in two <i>Kras</i>-mutant syngeneic mouse lung cancer models.
|
29339375 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC).
|
29296193 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Evidence to date indicates that TUSC2 behaves as a tumor suppressor in lung cancer; however, its role as a tumor suppressor for other tumor types has not been fully established.
|
28715648 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This ability to modify the tumor microenvironment suggests that TUSC2 could be added to checkpoint inhibitors to improve the treatment of lung cancer.
|
29296193 |
2017 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This ability to modify the tumor microenvironment suggests that TUSC2 could be added to checkpoint inhibitors to improve the treatment of lung cancer.
|
29296193 |
2017 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
TUSC2 restoration has been exploited as an anti-cancer therapy in various cancers in preclinical models, and clinically in patients with lung cancer.
|
28715648 |
2017 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This ability to modify the tumor microenvironment suggests that TUSC2 could be added to checkpoint inhibitors to improve the treatment of lung cancer.
|
29296193 |
2017 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
TUSC2 restoration has been exploited as an anti-cancer therapy in various cancers in preclinical models, and clinically in patients with lung cancer.
|
28715648 |
2017 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
TUSC2 restoration has been exploited as an anti-cancer therapy in various cancers in preclinical models, and clinically in patients with lung cancer.
|
28715648 |
2017 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This ability to modify the tumor microenvironment suggests that TUSC2 could be added to checkpoint inhibitors to improve the treatment of lung cancer.
|
29296193 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Addition of the thioredoxin reductase 1 inhibitor (TXNRD1) auranofin (AF) to NSCLC cells treated with combination of TUSC2 forced expression with erlotinib increased tumor cell apoptosis and inhibited colony formation.
|
27845352 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TXNRD1 overexpression rescued tumors from AF-TUSC2-erlotinib induced apoptosis.
|
27845352 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Restoration of FUS1 function in human non-small cell lung cancer (NSCLC) cells was found to significantly inhibit tumor cell growth and modulate the chemosensitivity of lung cancer cells.
|
26081814 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of all three TSGs were significantly different between NSCLC subtypes: RASSF1A and FUS1 expression levels were significantly lower in squamous cell carcinoma (SCC), and NPRL2/G21 in adenocarcinoma (AC).
|
26112163 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we restored TUSC2 gene expression in several wild type EGFR non-small cell lung cancer (NSCLC) cell lines resistant to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib and analyzed their sensitivity to erlotinib in vitro and in vivo.
|
26053020 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Restoration of FUS1 function in human non-small cell lung cancer (NSCLC) cells was found to significantly inhibit tumor cell growth and modulate the chemosensitivity of lung cancer cells.
|
26081814 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combination treatment with intravenous TUSC2 nanovesicles and erlotinib synergistically inhibited tumor growth and metastasis, and increased apoptotic activity.
|
26053020 |
2015 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Restoration of FUS1 function in human non-small cell lung cancer (NSCLC) cells was found to significantly inhibit tumor cell growth and modulate the chemosensitivity of lung cancer cells.
|
26081814 |
2015 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
TUSC2-erlotinib cooperativity in vitro could be reproduced in vivo in subcutaneous tumor growth and lung metastasis formation lung cancer xenograft mouse models.
|
26053020 |
2015 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Restoration of FUS1 function in human non-small cell lung cancer (NSCLC) cells was found to significantly inhibit tumor cell growth and modulate the chemosensitivity of lung cancer cells.
|
26081814 |
2015 |